Misyo (Methadone Hydrochloride)

Methadone Hydrochloride, the active ingredient in Misyo, is a synthetic opioid presented as an oral formulation for oral use. It is indicated for opioid dependence treatment and for the management of chronic severe pain in adult patients. The medication is formulated to provide long‑acting opioid receptor activation, allowing stable plasma concentrations and reducing the need for frequent dosing. GNH USA supplies Misyo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. All shipments meet EU regulatory requirements and are supported by comprehensive documentation.

Methadone Hydrochloride is used in opioid‑related pathways to manage dependence and pain.

Opioid dependence treatment: reduces withdrawal symptoms and cravings, facilitating stabilization. Chronic pain management: provides long‑acting analgesia for severe, persistent pain. Opioid substitution therapy: maintains steady opioid levels to prevent illicit drug use.

Methadone Hydrochloride may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Constipation - Nausea - Drowsiness - Dry mouth

Serious or Rare Side Effects: - Respiratory depression - QT interval prolongation - Severe hypotension

When prescribing Misyo, clinicians should consider several safety measures.

Assess patient history: evaluate prior opioid use and comorbidities. Monitor respiratory function: watch for depression, especially during initiation. Evaluate cardiac status: consider QT interval monitoring. Avoid use in acute respiratory depression: contraindicated in patients with severe respiratory compromise. Adjust dose in hepatic impairment: reduce dosage as needed. Store at room temperature: keep in original container, protect from moisture.

Methadone Hydrochloride interacts with several drug classes; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole): may increase methadone levels and risk of toxicity. - CNS depressants (e.g., benzodiazepines): can cause profound respiratory depression. - QT‑prolonging agents (e.g., quinidine): increase risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Anticholinergics (e.g., atropine): may exacerbate constipation.